These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 9796981

  • 1. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.
    Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
    [Abstract] [Full Text] [Related]

  • 2. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997 Oct; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 3. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
    DeNardo GL, DeNardo SJ.
    Cancer Biother Radiopharm; 2004 Feb; 19(1):85-92. PubMed ID: 15068616
    [Abstract] [Full Text] [Related]

  • 5. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
    DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, Shen S, Miers LA, deVere White RW, DeNardo GL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
    [Abstract] [Full Text] [Related]

  • 6. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
    DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL.
    J Nucl Med; 1998 May 01; 39(5):842-9. PubMed ID: 9591587
    [Abstract] [Full Text] [Related]

  • 7. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.
    J Nucl Med; 2000 May 01; 41(5):952-8. PubMed ID: 10809213
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.
    DeNardo GL, DeNardo SJ, Peterson JJ, Miers LA, Lam KS, Hartmann-Siantar C, Lamborn KR.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3865S-72S. PubMed ID: 14506184
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ, Zhong GR, Salako Q, Li M, DeNardo GL, Meares CF.
    J Nucl Med; 1995 May 01; 36(5):829-36. PubMed ID: 7738660
    [Abstract] [Full Text] [Related]

  • 10. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1998 May 01; 9(6):773-82. PubMed ID: 9815172
    [Abstract] [Full Text] [Related]

  • 11. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
    Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1192-8. PubMed ID: 16965873
    [Abstract] [Full Text] [Related]

  • 12. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [Abstract] [Full Text] [Related]

  • 13. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA.
    Cancer Res; 1992 Feb 15; 52(4):904-11. PubMed ID: 1737353
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, Renn O, Greiner DP, Kukis DL, Kronenberger SI.
    Cancer Res; 1994 Nov 15; 54(22):5937-46. PubMed ID: 7954426
    [Abstract] [Full Text] [Related]

  • 15. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 16. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.
    Clin Cancer Res; 2005 Nov 15; 11(22):8180-5. PubMed ID: 16299250
    [Abstract] [Full Text] [Related]

  • 17. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
    DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL.
    Proc Natl Acad Sci U S A; 1997 Apr 15; 94(8):4000-4. PubMed ID: 9108094
    [Abstract] [Full Text] [Related]

  • 18. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
    O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
    [Abstract] [Full Text] [Related]

  • 19. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.
    J Nucl Med; 2005 May 15; 46(5):850-8. PubMed ID: 15872360
    [Abstract] [Full Text] [Related]

  • 20. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec 15; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.